The stock price of DBV Technologies ADR (NASDAQ: DBVT) has surged by 10.37 when compared to previous closing price of 3.47, but the company has seen a 23.95% gain in its stock price over the last five trading sessions. benzinga.com reported 2024-12-12 that On Wednesday, DBV Technologies SA DBVT reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years.
Is It Worth Investing in DBV Technologies ADR (NASDAQ: DBVT) Right Now?
Moreover, the 36-month beta value for DBVT is 0.63. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DBVT is 20.44M and currently, short sellers hold a 2.99% of that float. On January 10, 2025, DBVT’s average trading volume was 252.46K shares.
DBVT’s Market Performance
DBVT stock saw an increase of 23.95% in the past week, with a monthly gain of 4.64% and a quarterly increase of 8.64%. The volatility ratio for the week is 5.80%, and the volatility levels for the last 30 days are 7.40% for DBV Technologies ADR (DBVT). The simple moving average for the past 20 days is 16.15% for DBVT’s stock, with a -17.04% simple moving average for the past 200 days.
Analysts’ Opinion of DBVT
Goldman gave a rating of “Neutral” to DBVT, setting the target price at $1.50 in the report published on May 10th of the previous year.
DBVT Trading at 14.20% from the 50-Day Moving Average
After a stumble in the market that brought DBVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.63% of loss for the given period.
Volatility was left at 7.40%, however, over the last 30 days, the volatility rate increased by 5.80%, as shares surge +9.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.60% lower at present.
During the last 5 trading sessions, DBVT rose by +23.95%, which changed the moving average for the period of 200-days by -51.90% in comparison to the 20-day moving average, which settled at $3.30. In addition, DBV Technologies ADR saw 23.95% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DBVT starting from Mohideen Pharis, who sale 565 shares at the price of $0.57 back on Nov 25 ’24. After this action, Mohideen Pharis now owns 111,110 shares of DBV Technologies ADR, valued at $322 using the latest closing price.
Mohideen Pharis, the Chief Medical Officer of DBV Technologies ADR, sale 342 shares at $0.53 during a trade that took place back on Nov 22 ’24, which means that Mohideen Pharis is holding 111,675 shares at $181 based on the most recent closing price.
Stock Fundamentals for DBVT
Current profitability levels for the company are sitting at:
- -9.15 for the present operating margin
- 1.0 for the gross margin
The net margin for DBV Technologies ADR stands at -8.92. The total capital return value is set at -1.68. Equity return is now at value -103.11, with -72.19 for asset returns.
Based on DBV Technologies ADR (DBVT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -150.22.
Currently, EBITDA for the company is -87.46 million with net debt to EBITDA at 0.38. When we switch over and look at the enterprise to sales, we see a ratio of 7.26. The receivables turnover for the company is 0.57for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.22.
Conclusion
To wrap up, the performance of DBV Technologies ADR (DBVT) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
